Instructions for Ostiveron capsules No. 90
Composition
1 capsule contains: active ingredient: microcrystalline hydroxyapatite complex StimuCalTM – 700 mg (mg); excipients: magnesium stearate (anti-caking agent), capsule shell: gelatin.
StimuCalTM includes: 168 mg (mg) of proteins (type I collagen and non-collagen peptides, including insulin-like growth factor type I and type II (IGF1 – 0.1995 μg (µg), IGF2 – 0.119 μg (µg)), transforming growth factor beta (TGF-β – 0.0175 μg (µg)), osteocalcin – 422.8 μg (µg)) and 466.9 mg (mg) of calcium hydroxyapatite (including 182 mg (mg) of calcium, 86.8 mg (mg) of phosphorus, 2.8 mg (mg) of magnesium, 44.8 μg (µg) of zinc, 2.73 μg (µg) of iron and 0.98 μg (µg) of boron).
Recommendations for use, method of administration and recommended daily dose
- Ostiveron is recommended to normalize the functional state of the musculoskeletal system in case of fractures: from the first day of the fracture and for 14 days it is recommended to take 1 capsule per day, washed down with a small amount of drinking water, preferably during meals. From the 15th day it is recommended to increase the dose to 3 capsules per day (divided into 2 doses), washed down with a small amount of drinking water, preferably during meals. On the recommendation of a doctor, the recommended daily dose may be increased. The course of use is determined by the doctor individually. The minimum recommended course of use is 1 month. Before use, it is recommended to consult a doctor.
- Ostiveron is recommended for the regulation of calcium-phosphorus metabolism, calcium deficiency in the body, osteoporosis: adults should take 3-6 capsules per day (divided into 2 doses), washed down with a small amount of drinking water, preferably during meals. On the recommendation of a doctor, the recommended daily dose may be increased. The course of use is determined by the doctor individually. The minimum recommended course of use is 1 month. Before use, it is recommended to consult a doctor.
Functional properties
Ostiveron contains microcrystalline hydroxyapatite complex StimuCalTM - a mineral-protein complex that is a regulator of calcium-phosphorus metabolism. The ossein-hydroxyapatite complex includes organic (ossein) and mineral (hydroxyapatite) components. The mineral component of the complex (hydroxyapatite) consists of mineral atoms arranged in a certain geometric order, contributes to the formation of the mineral matrix of the bone, and provides a biologically active connection with bone cells. Calcium and phosphorus, which are part of hydroxyapatite crystals, are necessary for the mineralization of osteoid and are the "building" material of bone. Due to the fact that calcium in hydroxyapatite is in a highly available form and in a physiological ratio with phosphorus (2:1), it is fixed in the bone, and its excretion in the urine is reduced.
Magnesium helps maintain normal calcium levels in bone tissue and participates in its metabolism. Magnesium inhibits calcium deposition on blood vessel walls and prevents bone demineralization.
Zinc has a stimulating effect on bone formation and mineralization, it directly activates aminoacyl-tRNA synthetase in osteoblast cells, which stimulates cellular protein synthesis. In addition, zinc inhibits osteoclastic bone resorption by inhibiting osteoclasts.
Iron participates in the metabolism of collagen, from which bone tissue, including trabeculae, is built.
Boron has a pronounced effect on the growth processes of bone tissue and cartilage cells, increasing the level of osteogenesis proteins - osteocalcin, type 1 collagen, bone morphogenesis proteins 4, 6 and 7, as well as osteopontin, bone sialoprotein (BSP gene), Runx 2 protein. Boron affects the metabolism of vitamin D and improves calcium absorption. It regulates the activity of parathyroid hormone, and through it affects the entire phosphorus-calcium metabolism. The normal metabolism of phosphorus, calcium and vitamin D3 depends on boron.
The organic component is represented by proteins and peptides (growth factors, osteocalcin, collagen, etc.). Due to the presence of growth factors in ossein (transforming growth factor - beta (TGF-β), insulin-like growth factors - 1 and 2 (IGF1, IGF2)), the proliferation and differentiation of osteoblasts is stimulated. TGF-β has a significant effect on bone metabolism, in particular the proliferation of the cell pool and the main substance of bone tissue. One of the key growth factors that takes an active part in all phases of the reparative process during a fracture. Activation of osteoblasts by growth factors contributes to their increased biosynthesis of type I collagen, proteoglycans and non-collagenous proteins, on the basis of which bone mineralization processes occur. Growth factors also reduce bone resorption by inhibiting the development of osteoclast precursor cells.
Osteocalcin, as a component of the complex, plays an important role in the formation of the organic matrix, promoting the bonding of hydroxyapatite crystals and the mineralization of collagen.
Precautions for use
Do not exceed the recommended daily dose. Ostiveron should not be used as a substitute for a balanced diet.
Contraindication
- individual sensitivity to any of the components, hypercalcemia, hypercalciuria, urolithiasis, tissue calcification, severe renal dysfunction, hyperproliferative processes.
Storage conditions
Store in the original packaging in a dry place, protected from light and out of reach of children, at room temperature.
Not a medicine. Non-GMO.
Release form
- hard capsules No. 30 in blisters, No. 90 in a jar and No. 180 in a jar.
Number of capsules per package: indicated on the package.
Weight of contents of 1 capsule: 710 mg (mg) ± 10%.
Total weight of 1 capsule: 806 mg (mg) ± 10%.
Expiration date
24 months from the date of manufacture.
Producer
Name and location and telephone number of the manufacturer: Solepharm Ltd., Latvia, registered office: Alksnu 4, Jaunmarupe, Marupes novads, LV – 2166, Latvia; address for correspondence: Alksnu 4, Jaunmarupe, Marupes novads, LV – 2166, Latvia, tel.: +37129484403 / Alksnu 4, Jaunmarupe, Marupes novads, LV – 2166 / Plienciema 16, Marupe, LV-2167 Latvia; tel.: +37129484403.
Authorized representative in Ukraine: LLC "BAZKID PHARM GROUP", Ukraine, 01021, Kyiv, Hrushevskoho St., 28/2, n/p 43; tel.: +38(044) 337-25-38.
